Integra LifeSciences Holdings Corporation (NASDAQ:IART) has been given an average recommendation of “Buy” by the fourteen analysts that are currently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $54.10.

A number of analysts have recently weighed in on the stock. Oppenheimer Holdings, Inc. set a $60.00 price target on shares of Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a report on Saturday, June 24th. UBS AG reaffirmed a “buy” rating and issued a $60.00 price objective (up from $48.00) on shares of Integra LifeSciences Holdings Corporation in a research report on Friday, June 9th. Barclays PLC reaffirmed an “equal weight” rating and issued a $53.00 price objective (up from $47.00) on shares of Integra LifeSciences Holdings Corporation in a research report on Tuesday, September 12th. Jefferies Group LLC reissued a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a research report on Sunday, September 10th. Finally, BidaskClub lowered shares of Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 24th.

In other news, Director Barbara B. Hill acquired 5,050 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The stock was acquired at an average cost of $49.33 per share, with a total value of $249,116.50. Following the completion of the acquisition, the director now owns 44,772 shares of the company’s stock, valued at $2,208,602.76. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Donald E. Morel, Jr. acquired 10,000 shares of the firm’s stock in a transaction dated Friday, August 4th. The stock was purchased at an average cost of $49.25 per share, with a total value of $492,500.00. Following the completion of the acquisition, the director now directly owns 29,612 shares of the company’s stock, valued at approximately $1,458,391. The disclosure for this purchase can be found here. Insiders purchased 17,550 shares of company stock valued at $864,842 over the last ninety days. 21.50% of the stock is currently owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC raised its stake in shares of Integra LifeSciences Holdings Corporation by 6.2% during the second quarter. FMR LLC now owns 8,084,562 shares of the life sciences company’s stock worth $440,690,000 after purchasing an additional 468,678 shares during the last quarter. BlackRock Inc. grew its holdings in Integra LifeSciences Holdings Corporation by 307,726.8% in the first quarter. BlackRock Inc. now owns 7,455,564 shares of the life sciences company’s stock valued at $314,104,000 after purchasing an additional 7,453,142 shares during the last quarter. Vanguard Group Inc. grew its holdings in Integra LifeSciences Holdings Corporation by 116.7% in the first quarter. Vanguard Group Inc. now owns 5,656,048 shares of the life sciences company’s stock valued at $238,289,000 after purchasing an additional 3,046,488 shares during the last quarter. Champlain Investment Partners LLC grew its holdings in Integra LifeSciences Holdings Corporation by 125.2% in the first quarter. Champlain Investment Partners LLC now owns 4,438,760 shares of the life sciences company’s stock valued at $187,005,000 after purchasing an additional 2,468,145 shares during the last quarter. Finally, Capital Research Global Investors grew its holdings in Integra LifeSciences Holdings Corporation by 227.0% in the second quarter. Capital Research Global Investors now owns 3,897,288 shares of the life sciences company’s stock valued at $212,441,000 after purchasing an additional 2,705,488 shares during the last quarter. Institutional investors and hedge funds own 84.90% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Integra LifeSciences Holdings Corporation (IART) Given Consensus Recommendation of “Buy” by Brokerages” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.watchlistnews.com/integra-lifesciences-holdings-corporation-iart-given-consensus-recommendation-of-buy-by-brokerages/1611232.html.

Shares of Integra LifeSciences Holdings Corporation (IART) traded down 0.23% during midday trading on Friday, reaching $51.65. 314,165 shares of the company’s stock were exchanged. Integra LifeSciences Holdings Corporation has a 12-month low of $37.71 and a 12-month high of $56.42. The stock’s 50 day moving average is $50.65 and its 200-day moving average is $49.10. The stock has a market cap of $4.03 billion, a PE ratio of 62.99 and a beta of 0.71.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last posted its quarterly earnings results on Wednesday, July 26th. The life sciences company reported $0.45 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.45. Integra LifeSciences Holdings Corporation had a net margin of 6.27% and a return on equity of 16.79%. The firm had revenue of $282.16 million for the quarter, compared to analysts’ expectations of $283.58 million. During the same period in the prior year, the business posted $0.40 earnings per share. The business’s revenue for the quarter was up 13.2% on a year-over-year basis. On average, equities analysts expect that Integra LifeSciences Holdings Corporation will post $1.90 EPS for the current year.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Analyst Recommendations for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.